{"id":"W4411603000","doi":"10.1182/bloodadvances.2025015881","title":"Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children","funders":"Cancer Moonshot; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Kite Pharma; Takeda Oncology; National Institutes of Health; MorphoSys; Health Resources and Services Administration; Syndax Pharmaceuticals; BeiGene; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; Jazz Pharmaceuticals; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; StemCyte; Actinium Pharmaceuticals; CareDx; University of Pittsburgh; HistoGenetics; U.S. Department of Defense; Moonshot Research and Development Program; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Mallinckrodt Pharmaceuticals; Astellas Pharma US; U.S. Navy; Gateway for Cancer Research; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Incyte; Pfizer; Amgen; Atara Biotherapeutics; National Cancer Institute; Servier; Gilead Sciences","keywords":"Medicine; Refractory (planetary science); Internal medicine; Gastroenterology; Pediatrics; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002551334,0.0001589071,0.0003400847,0.0001215406,0.00007456541,0.00004041975,0.0005691742,0.00003483233,0.0001214015],"category_scores_gemma":[0.0001998633,0.00009885885,0.00004857946,0.0006472186,0.0001618993,0.0001723041,0.0001607716,0.0002126156,0.000003471337],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004366028,"about_ca_system_score_gemma":0.000134606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001567771,"about_ca_topic_score_gemma":0.01222972,"domain_scores_codex":[0.9984941,0.0000641727,0.0002558402,0.0005099648,0.0003632596,0.0003126453],"domain_scores_gemma":[0.997701,0.0006213185,0.00009643361,0.001426153,0.00009349778,0.00006160878],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002223126,0.0005951548,0.952347,0.00009124671,0.0005119216,0.00001828577,0.00007842584,0.00001093229,0.004077081,0.0001190409,0.004032359,0.03589537],"study_design_scores_gemma":[0.008577385,0.0004358648,0.8109422,0.000375952,0.0004956542,7.175803e-7,0.000250885,0.0001158871,0.007002028,0.0006619373,0.1709343,0.0002072026],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869542,0.002876755,0.000226593,0.001623679,0.0001211684,0.001331383,0.0005008181,0.00005758193,0.006307846],"genre_scores_gemma":[0.9747265,0.001528247,0.005547227,0.00110926,0.0003177729,0.00015982,0.002075345,0.00005619987,0.01447964],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1669019,"threshold_uncertainty_score":0.6824469,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07493340698245726,"score_gpt":0.4053863752245954,"score_spread":0.3304529682421382,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}